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Risk of diabetes after para-aortic radiation for testicular cancer
Harmke J. Groot1, Jourik A. Gietema2, Berthe M. P. Aleman3, Luca Incrocci4, Ronald de Wit5, J. Alfred Witjes6, Gerard Groenewegen7,
Peter de Brouwer8, Otto W. M. Meijer9, Maarten C. C. M. Hulshof10, Hetty A. van den Berg11, Tineke J. Smilde12, Ben G. L. Vanneste13,
Maureen J. Aarts14, Alphonsus C. M. van den Bergh15, J. Martijn Kerst16, Alexandra W. van den Belt-Dusebout1, Sjoukje Lubberts17,
Katarzina Jóźwiak18, Simon Horenblas19, Flora E. van Leeuwen1 and Michael Schaapveld1
BACKGROUND: While the risk of diabetes is increased following radiation exposure to the pancreas among childhood cancer
survivors, its association among testicular cancer (TC) survivors has not been investigated.
METHODS: Diabetes risk was studied in 2998 1-year TC survivors treated before 50 years of age with orchidectomy with/without
radiotherapy between 1976 and 2007. Diabetes incidence was compared with general population rates. Treatment-speciﬁc risk of
diabetes was assessed using a case–cohort design.
RESULTS: With a median follow-up of 13.4 years, 161 TC survivors were diagnosed with diabetes. Diabetes risk was not increased
compared to general population rates (standardised incidence ratios (SIR): 0.9; 95% conﬁdence interval (95% CI): 0.7–1.1). Adjusted
for age, para-aortic radiotherapy was associated with a 1.66-fold (95% CI: 1.05–2.62) increased diabetes risk compared to no
radiotherapy. The excess hazard increased with 0.31 with every 10 Gy increase in the prescribed radiation dose (95% CI: 0.11–0.51,
P= 0.003, adjusted for age and BMI); restricted to irradiated patients the excess hazard increased with 0.33 (95% CI: −0.14 to 0.81,
P= 0.169) with every 10 Gy increase in radiation dose.
CONCLUSION: Compared to surgery only, para-aortic irradiation is associated with increased diabetes risk among TC survivors.
British Journal of Cancer (2018) 119:901–907; https://doi.org/10.1038/s41416-018-0248-x
INTRODUCTION
Several studies among childhood cancer and Hodgkin lymphoma
survivors have reported that infradiaphragmatic radiotherapy may
increase risk of diabetes.1–4 A recent study by van Nimwegen and
colleagues showed that Hodgkin lymphoma survivors treated with
para-aortic irradiation at doses of ≥36 Gray had a 1.8-fold
increased risk of diabetes compared to patients without radio-
therapy.4 Lower doses, which are more common in testicular
cancer (TC) treatment, did not signiﬁcantly increase diabetes risk
in this study.
Although para-aortic radiotherapy (PAO-RT) is no longer used
for treatment of non-seminoma patients nowadays and only rarely
for treatment of stage I seminoma patients, it has long been part
of TC treatment. PAO-RT for TC will generally result in irradiation of
the head and body of the pancreas, which contains part of the
insulin-producing beta-cells.5 Only one previous study assessed
diabetes prevalence after radiotherapy for testicular cancer.
Haugnes et al. observed a diabetes prevalence of 10.2% among
patients treated with radiotherapy in 1980–1994 and screened for
(risk factors for) cardiovascular disease (CVD) in 2008, which was
2.3-fold higher compared to prevalence among general popula-
tion controls.6 The effect of radiation dose on diabetes risk was
not assessed in this study. It is important to ascertain whether
radiotherapy is associated with increased diabetes risk among TC
survivors, since diabetes is an important predictor of premature
mortality7 and may increase risk of coronary artery disease.8,9
Establishing a dose–response relationship is clinically important
since radiation doses to organs at risk can be signiﬁcantly reduced
with modern radiation techniques and dose constraints to the
pancreas can be introduced in radiation planning for TC and other
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malignancies. Therefore, this study aims to assess the association
of radiation dose and diabetes risk after PAO-RT in a large
multicenter cohort of TC survivors.
METHODS
Study population and design
A hospital-based cohort was established including 6312 TC
patients who were treated from January 1976 to December
2007 in 13 Dutch hospitals and were younger than 50 years at TC
diagnosis. This cohort included 1874 5-year TC survivors treated
between 1976 and 1995, entered in previous studies on
cardiovascular disease (CVD) risk among TC survivors.10,11 Patients
were identiﬁed through tumour registries and through the
Netherlands Cancer Institute. Details on patient selection are
presented in Supplemental Figure S1. For all patients in our
hospital-based cohort, basic tumour and primary treatment
characteristics were available.
In the current study, we aim to assess risk of diabetes among
patients treated with radiotherapy as part of their primary
treatment compared to risk of diabetes among patients treated
with surgery only. Therefore, we ﬁrst selected all patients from the
hospital-based cohort who received either surgery only or surgery
with radiotherapy as part of primary treatment and were aged
between 12 and 50 years at orchidectomy and were alive 1 year
after TC diagnosis (N= 3746, Supplemental ﬁgure S1). For 68.6%
of the cohort (N= 2568) and for 76.7% of the subcohort (N= 544),
diabetes and cardiovascular disease follow-up was available
through the GP and/or medical ﬁles until at least January 2011.
We excluded all patients without any cardiovascular disease
follow-up (575 patients); those who died or were lost to follow-up
within 1 year (71 patients), those who received chemotherapy in
the ﬁrst year after TC diagnosis (85 patients) and who developed
diabetes before TC (1 patient) or within 1 year after TC diagnosis
(16 patients). This left 2998 patients for analysis. We subsequently
identiﬁed all patients who had developed diabetes in our study
cohort (N= 161, Supplemental ﬁgure S1).
Similarly, we selected all patients from the subcohort who had
received either surgery only or surgery with radiotherapy as
primary treatment and who had survived at least 1 year after TC
diagnosis (N= 614).
We used a case-cohort design to facilitate detailed treatment
data collection while allowing assessment of multiple treatment-
associated outcomes.12 A hospital-stratiﬁed subcohort comprising
15% of the base cohort (25% in the two coordinating hospitals)
was randomly selected, without taking cardiovascular or oncolo-
gical follow-up into account. This subcohort comprised 1175 TC
patients. For all randomly sampled patients in the subcohort and
for all patients who developed diabetes (which includes patients
who developed diabetes and were sampled in the subcohort),
detailed treatment data were abstracted from the medical charts,
including chemotherapy regimens, number of cycles and cumu-
lative doses, radiotherapy ﬁelds and doses for primary treatment
as well as relapse treatment. The study protocol was submitted to
the Institutional Review Board of the Netherlands Cancer Institute,
which waived the requirement for individual patient consent.
Treatment
All patients underwent orchidectomy. Radiotherapy for stage I and
II seminomas typically comprised irradiation of the infradiaphrag-
matic para-aortic, ipsilateral, iliacal and inguinal lymph nodes.
Irradiation of the para-aortic and iliac lymph nodes constitutes the
dogleg radiation ﬁeld.11,13 For left-sided tumours the para-aortic
ﬁelds were usually extended to include the left renal hilar nodes.
The radiation dose used in the treatment of seminoma patients
gradually declined over time from 30 to 35 Gray in the 1980s to 26
Gray from 1990 onwards.10,14 Since the mid-2000s, stage I
seminoma patients are increasingly treated with either
surveillance, or in case of at least two risk factors, 20 Gray
radiotherapy or 1 cycle of carboplatin (AUC 7).15–17 Before 1985,
treatment for stage I or IIA non-seminoma frequently included
adjuvant radiotherapy with a dose of 40–50 Gray in 20–25
fractions.13,14 From 1985 onwards, stage I non-seminoma patients
were generally treated under watchful waiting protocols, depend-
ing on disease severity and prognostic factors.13,17
Outcome assessment
Information on date of diagnosis, type of and treatment for diabetes,
was obtained between 2013 and 2016 from the medical records
and/or questionnaires sent to the patient’s general practitioner (GP)
and from medical correspondence with the treating physician. In
Dutch guidelines for general practitioners, diabetes is typically
deﬁned as fasting plasma glucose ≥7.0mmol/l.18 Population screen-
ing for diabetes is not part of current Dutch GP guidelines, hence,
diabetes case ascertainment was based on clinical presentation to
regular care (see Supplement S2).
Statistical analysis
Time at risk started 1 year after start of TC treatment and ended at
date of diabetes diagnosis, date of death or date of last follow-up,
whichever occurred ﬁrst. Patients who relapsed were censored at
the date of relapse if treatment for the relapse included
chemotherapy and relapse treatment was started 1 year or more
after TC diagnosis. The last medical follow-up as recorded in the
medical ﬁles was used when no follow-up information from GP
questionnaires was available. In the cohort, follow-up for diabetes
and other cardiovascular disease risk factors was derived from
information from the medical record and the GP in 32.2%, from
the GP only in 61.4% and from the medical record only in 6.4% of
the patients; in the subcohort these percentages were 81.6%, 2.9%
and 15.5%, respectively. In total, 11.2% of the patients with
diabetes in the subcohort (four patients) were identiﬁed through
information from the medical record only.
Comparison with the general population. Incidence of diabetes
was compared with sex-, age- (5-year strata), and calendar year-
speciﬁc diabetes incidence rates in the Dutch population. Diabetes
incidence rates for the Dutch population were obtained from
electronic health records of general practitioners participating in
NIVEL Primary Care Database and were available for 2002–2016
(Number NZR-00316.030). Therefore, analyses were left censored
at January 1, 2002. For more details on diabetes population,
reference rates and calculation of standardised incidence ratios we
refer to Supplemental ﬁle S3.
Case-cohort comparisons: assessing the relationship between treat-
ment and diabetes risk. Cumulative incidence of diabetes was
estimated in the presence of death as competing risk, and trends
over time were evaluated using competing risk regression models
with adjustment for age.19 Missing information on covariates were
imputed using chained equations (MICE), ignoring patient clusters,
and creating 20 datasets18,19. Disease stage, radiation ﬁeld and
smoking were imputed with multinomial logistic regression, while
weight, height and radiation dose were imputed using linear
regression. In all imputation models, year and age at treatment,
histology, age, hospital of diagnosis, diabetes status and
cumulative hazards of diabetes calculated with a Cox regression
model before imputation, were included as extra covariates.
Associations of TC treatment with diabetes risk were assessed
using multivariable Cox regression models with time since TC
treatment as time scale. Barlow’s inverse probability weights were
used to adjust the partial likelihood function for our case-cohort
design12. TC treatment was entered in the model as a time-varying
variable. Effects of treatment were evaluated accounting for the
effects of other covariates where appropriate. Modiﬁcation of a
radiation-associated diabetes risk was assessed by inclusion of
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Table 1. Patient characteristics for 1-year testicular germ cell cancer survivors treated between 1976 and 2007 with primary surgery with/without
radiotherapy
Patient characteristic Base cohort Subcohorta Diabetes after TC
N % N % N %
All patients 2998 614 161
Histology
Seminoma 2071 69.1 414 67.4 131 81.4
Non-seminoma 927 30.9 200 32.6 30 18.6
Age at testicular cancer, years
Median±IQR 33.3 27.9–39.0 33.3 28.0–39.0 37.4 32.1–42.0
<30 1012 33.8 213 34.7 28 17.4
30–40 1349 45.0 271 44.1 73 45.3
40–50 637 21.3 130 21.2 60 37.3
Treatment period
1976–1985 477 15.9 93 15.2 63 39.1
1986–1995 916 30.6 216 35.2 50 31.1
1995–2007 1605 53.5 305 49.7 48 29.8
Follow-up duration, years
Median±IQR 13.4 8.3–20.5 14.6 9.6–21.3 14.3 8.9–21.1
0–4 years 153 5.2 43 7.0 18 11.2
5–9 years 641 21.4 126 20.5 36 22.4
10–14 years 738 24.6 149 24.3 34 21.1
15–19 years 578 19.3 107 17.4 23 14.3
20–24 years 434 14.5 101 16.5 24 14.9
25–29 years 243 8.1 52 8.5 16 9.9
≥30 years 211 7.0 36 5.9 10 6.2
Relapse, % yes 79 2.6 30 4.9 3 1.9
Treatment for TC (total treatment)
Hemi-orchidectomy only — — 208 33.9 28 17.4
Radiotherapy — — 406 66.1 133 82.6
RT ﬁeld
No PAO/ DL radiotherapyb — — 208 33.9 28 17.4
Radiotherapy, PAO — — 164 26.7 39 24.2
Radiotherapy, DL — — 229 37.3 87 54.0
Unknown — — 13 2.1 7 3.7
Prescribed PAO-radiation dose
No PAO radiotherapy b — — 208 33.9 28 17.4
<26 Gray — — 86 14.0 34 21.1
26–32 Gray — — 233 38.0 69 42.9
≥32 Gray — — 48 7.8 17 10.6
Dose unknown — — 26 4.2 6 3.7
Field unknown — — 13 2.1 7 4.3
Median dose (IQR) 26 26-26 26 25-30
Cardiovascular disease risk factors
BMI at TC diagnosis
<30 kg/m2 — — 215 35.0 57 34.4
≥30 kg/m2 — — 21 3.4 15 9.3
Unknown — — 378 61.6 89 55.3
Diabetes, % yesc 39 6.4 161 100
Diabetes type
Insulin dependent — — 3 7.7 24 14.9
Non-Insulin dependent — — 32 82.0 123 76.4
Unknown type or treatment — — 4 10.3 14 8.7
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interaction terms for age, obesity (BMI > 30 kg/m2) and smoking
with radiotherapy. To assess an excess relative risk for prescribed
radiation dose in relation to diabetes risk in our case-cohort
setting, the linear increase in the HRs over categories of prescribed
dose was estimated separately for each imputed data set using
weighted least square regression with weights equal to 1/variance
of each HR and subsequently averaged over all 20 data sets. Cox
regression model estimates from the imputed data sets were
pooled using Rubin’s rule.20 Dose categories were chosen such
that each category represented at least ﬁve diabetes cases (0, ≤24,
25, 26, 27–30, 31–35, 36–40 and ≥40 Gray) and conﬁdence
intervals of the HRs were based on Wald test. The proportional
hazards assumption was assessed using residual-based methods.
STATA (version 13.1, Statacorp LP, College Station, TX) statistical
software was used for analysis. A P ≤ 0.05 was considered
signiﬁcant.
RESULTS
Patient characteristics
Our study cohort comprised 2071 (69.1%) seminoma and 927 non-
seminoma TC patients (30.9%). Median age at TC treatment was
33.3 years (Interquartile range (IQR): 27.9–39.0 years). The median
follow-up was 13.4 years, during which 161 TC patients (5.3%)
developed diabetes. For 29.6% of the TC patients, follow-up
exceeded 20 years. Among patients with diabetes, the median
interval until diabetes was 14.3 years (IQR: 8.9–21.1 years). The
median age at TC treatment was 37.4 years (IQR: 32.1–42.0 years)
for patients with diabetes; the median age at diabetes diagnosis
was 51.9 years (IQR: 45.1–59.2 years).
Of all patients in the subcohort, comprising 414 seminoma
(67.4%) and 200 non-seminoma patients (32.6%), 406 patients
(66.1%) had received radiotherapy (Table 1). Median follow-up was
15.8 years (IQR: 8.4–23.4 years) for patients treated with surgery
only and 11.8 years (IQR: 6.2–19.8 years) for patients treated with
radiotherapy. Of the seminoma patients in the subcohort, 6.3%
underwent only surgery. The median radiotherapy dose to the
para-aortic ﬁeld was 30 Gray (range: 16–70 Gray) in 1976–1985
and decreased to 26 Gray (range: 17–51 Gray) during 1986–1995
(Supplemental table S4 and supplemental ﬁgure S5). Of the non-
seminoma patients treated before 1985, 31.9% received infra-
diaphragmatic radiotherapy with a median dose of 40 Gray (range:
30–70).
Diabetes risk compared to the general population: case-cohort
analysis
Diabetes risk among TC patients did not differ from the diabetes
risk expected based on incidence rates for the general Dutch male
population (standardised incidence rate (SIR): 0.9, 95% CI: 0.7–1.1,
Supplemental table S6). The SIR for diabetes was not increased for
patients treated with radiotherapy (SIR: 1.0, 95% CI: 0.8–1.2) and
diabetes risk did not differ by age at TC diagnosis (P-
heterogeneity: 0.970). SIRs were similar in the full cohort analysis,
although risk was lower than expected for non-irradiated patients
(SIR: 0.4, 95% CI: 0.3–0.6).
Diabetes risk after infradiaphragmatic radiotherapy: case-cohort
analyses
The cumulative incidence of diabetes was 6.1% (95% CI: 5.0–7.4%)
at 20 years and 15.6% (95% CI: 12.4–19.2%) at 30 years after TC
treatment. Adjusted for age at TC diagnosis patients treated with
para-aortic radiotherapy had a signiﬁcantly higher risk of diabetes
than patients who underwent only surgery (P < 0.001; Fig. 1).
Patients with a prescribed radiation dose of >26 Gray to a para-
aortic ﬁeld had a 30-year cumulative incidence of 16.7% (95% CI:
11.9–22.2%), compared to a 30-year cumulative incidence of 9.5%
(95% CI: 5.0–15.7%) for patients treated with surgery only (P value:
0.122, adjusted for age).
Table 1 continued
Patient characteristic Base cohort Subcohorta Diabetes after TC
N % N % N %
Hypercholesterolemia at TC diagnosis
Yes — — 5 0.8 3 1.9
No — — 574 93.5 141 87.6
Unknown — — 35 5.7 17 10.6
Hypertension at TC diagnosis
Yes — — 10 1.6 9 5.6
No — — 568 92.5 136 84.5
Unknown — — 36 5.9 16 9.9
Smoking status at TC diagnosis
Yes — — 181 29.5 55 34.2
No — — 229 37.3 74 46.0
Unknown — — 204 33.2 32 19.9
Vital status at date of last contact
Alive 2884 95.6 587 95.6 135 83.9
Died 97 3.2 22 3.6 26 16.2
Emigrated 37 1.2 5 0.8 0 0
Age at end of follow-up
Median±IQR 48.2 40.9–55.7 47.4 39.7–54.7 51.9 45.1–59.2
PAO para-aortic ﬁeld, DL Dog-Leg ﬁeld, BMI body mass index (in kg/m2)
aIn the subcohort 39 patients had developed diabetes (6.4% of subcohort)
bincludes infradiaphragmatic ﬁelds other than para-aortic radiotherapy only or dog leg, i.e. iliac/inguinal or scrotal radiation ﬁelds.
c7 of the 161 diabetes cases developed a pancreatic carcinoma before (N=2) around (N=4) or after (N=1) their diabetes diagnosis. Median time to diabetes
was 17.8 years (IQR: 11.1–26.1) for these patients
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Adjusted for age, para-aortic RT was associated with a 1.66-fold
(95% CI: 1.05–2.62; Table 2) increased diabetes risk compared to
no radiotherapy. When adjusting for BMI and age (as continuous
variables), risk decreased to 1.54 (95% CI: 0.96–2.45). A radiation
dose of ≤26 Gray to the para-aortic ﬁeld was associated with a
1.29-fold (95% CI: 0.79–2.11) increased diabetes risk while doses of
27–32 Gray and ≥33 Gray were associated with a 2.26-fold (95% CI:
1.22–4.21) and a 1.94-fold (95% CI: 0.95–3.97) increased diabetes
risk, respectively (P-trend: 0.011). The excess hazard increased with
0.31 with every 10 Gray increase in the prescribed radiation dose
(95% CI: 0.11–0.51, P= 0.003, Fig. 2). The excess risk among
irradiated patients increased with 0.33 (95% CI: −0.14 to 0.81, P=
0.169) with every 10 Gy increase in radiation dose.
Obesity at TC diagnosis was an independent risk factor for
diabetes, associated with a 2.52-fold (95% CI: 1.31–4.87) increased
diabetes risk, but did not modify the association between
radiotherapy and diabetes risk (P-interaction= 0.496). The effect
of infradiaphragmatic radiotherapy on diabetes risk was also not
modiﬁed by smoking or age. Complete case analyses, which only
included patients who had no missing data on radiation ﬁelds and
dose, provided similar results (Supplemental table S7).
Table 2. Multivariable analysis for diabetes risk by treatment among TC survivors (case-cohort study with detailed treatment data)
Adjusted for age Adjusted for age and BMI at TC diagnosis (continuously)
n/N HR 95% CI HR 95% CI
Radiotherapya
No 27/196 1 ref 1 ref
Yes 134/379 1.66 1.05–2.62 1.54 0.96–2.45
P-heterogeneity 0.030 0.074
Radiotherapy ﬁeld a
No PAO-radiotherapy 27/196 1 ref 1 ref
PAO-radiotherapy, left(incl. bilateral) 58/172 1.62 0.99–2.68 1.46 0.87–2.46
PAO-radiotherapy, right b 74/199 1.71 1.05–2.77 1.61 0.98–2.64
Other infradiaphragmatic ﬁelds 2/8 1.26 0.25–6.45 1.16 0.24–5.67
P -heterogeneity 0.156 0.204
Radiotherapy dosea
No para-aortic radiotherapy 27/196 1 ref 1 ref
≤26 Gray 80/281 1.45 0.91–2.32 1.29 0.79–2.11
27–32 Gray 35/46 2.39 1.31–4.35 2.26 1.22–4.21
≥33 Gray 19/52 1.88c 0.92–3.86 1.94c 0.95–3.97
P -heterogeneity 0.024 0.028
P -trend 0.013 0.011
BMI at TC diagnosis
<30 kg/m2 129/531 1 ref — —
≥30 kg/m2 32/44 2.52 1.31–4.87 — —
P -heterogeneity P<0.001
Smoking status at TC diagnosis
No 94/330 1 ref — —
Yes 67/245 0.94 0.64-1.37 — —
P -heterogeneity 0.625
n/N Median number of cases/median number of non-cases in the 20 imputed and pooled data sets
PAO para-aortic radiotherapy, BMI body mass index (kg/m2)
aPrimary and/or follow-up treatment
bDiabetes risk was not signiﬁcantly different between left and right sided PAO irradiation, P-heterogeneity, adjusted for age: 0.084; P-heterogeneity, adjusted
for age and BMI: 0.489
cPara-aortic RT dose 27-32 Gy and >32 Gy versus ≤26 Gy, P-hetero ≤0.016 and P-hetero ≤0.093, respectively (median dose: 26 Gy in category ≤26Gy, 30 Gy in
category 27–32 Gy and 40 Gy in category ≥33 Gy)
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Fig. 1 Incidence of diabetes among testicular cancer survivors
treated with para-aortic radiotherapy compared to orchidectomy
only. PAO para-aortic irradiation. Diabetes incidence was signiﬁ-
cantly increased after para-aortic radiotherapy (P < 0.001)
Risk of diabetes after para-aortic radiation for testicular cancer
HJ Groot et al.
905
DISCUSSION
In this large cohort study we observed a 1.66-fold increased risk of
diabetes among TC survivors treated with para-aortic radiotherapy
compared to TC survivors treated with surgery only, adjusted for
age. Diabetes risk increased with a higher para-aortic radiation
dose. However, diabetes risk after exposure to radiation was not
increased compared to that of males in the Dutch general
population, while diabetes risk was lower than expected among
survivors treated with surgery only.
Four studies previously investigated diabetes risk after para-
aortic radiotherapy in cancer survivors.1,2,4 In a French–British
cohort, de Vathaire and colleagues found an 11-fold increased
diabetes risk among childhood cancer survivors irradiated with 20
Gray to the pancreatic tail compared to those not treated with
radiotherapy; risk increased with increasing dose up to ≥30 Gray.
Meacham and colleagues observed a 1.8-fold increased risk of
developing diabetes among childhood cancer survivors compared
to sibling controls.2 In particular, high diabetes risks were
observed after treatment with radiotherapy, total body irradiation,
alkylating agents and treatment at ages <4 years. Among HL
survivors, van Nimwegen and colleagues observed a 1.8-fold
increased risk of diabetes after para-aortic radiotherapy with a
prescribed dose of ≥36 Gray compared to no para-aortic radio-
therapy.4 So far, only one cohort study investigated diabetes risk
after radiotherapy for testicular cancer. Haugnes and colleagues
found a higher prevalence of diabetes after radiotherapy exposure
(10.2%, 38 diabetes patients) compared to surgery only (4.0%, 8
diabetes patients), but did not provide relative risk estimates.6
Although para-aortic radiotherapy for TC does not include the
pancreatic tail and generally lower para-aortic doses are used
compared to treatment of childhood cancer and HL patients,
infradiaphragmatic radiotherapy was associated with an elevated
diabetes risk in TC survivors. Somewhat surprisingly, patients
treated with a para-aortic dose ≥33 Gray did not have a higher
diabetes risk than patients who received doses ≤26 Gray.
However, since only a small number of patients had doses ≥33
Gray, our power to reliably establish an increased diabetes risk
within this dose category was low.
Diabetes induced by infradiaphragmatic radiotherapy may result
from direct damage to the pancreatic beta-cell Islets of
Langerhans1,2,4 or to the pancreatic microvasculature.21,22 A study
in primates showed that pancreatic radiotherapy induced degranu-
lation, vacuolisation, mitochondrial destruction and impaired insulin
secretion shortly after treatment.23 Adjuvant radiotherapy has also
been shown to reduce beta-cell function and insulin secretion
capacity of the pancreas in 1-year gastric cancer survivors.22
Meacham and colleagues hypothesised that the radiotherapy effect
is independent of obesity and therefore a result of beta-cell
deﬁciency.2 Others found a marginally but not signiﬁcantly larger
diabetes risk among those with increased BMI.1,4 In our study,
obesity at baseline was an independent risk factor for diabetes but
did not modify radiotherapy-associated diabetes risk.
The pathway from para-aortic radiotherapy to diabetes could
also be modiﬁed by subclinical hypogonadism after orchidectomy,
which has been shown to increase the risk of developing a
metabolic syndrome.24 Hypogonadism is associated with increased
insulin insensitivity and diabetes risk.25,26 In the study of Haugnes
and colleagues, a 2.3-fold increased odds for diabetes was
observed after radiation compared to surgery only.6 Serum
testosterone levels were lower after radiation compared to surgery
only, but patients with orchidectomy only did not experience
increased diabetes risk compared to general population controls.6
In our study the prevalence of hypogonadism was similar after
radiation versus surgery (16% after orchidectomy only and 18%
after radiotherapy). Therefore, this pathway does not appear to
play a major role in diabetes etiology.
We observed a fairly large number of incident diabetes cases
(N= 161). Our risk estimates may underestimate the true risk, as
we may have missed asymptomatic diabetes cases. As a booster
dose was not recorded, we may also have underestimated the true
dose to the pancreas in some patients, which could have
attenuated our risk estimates for the association with prescribed
radiation dose. Our study provides reliable risk estimates for the
association of PAO-RT and diabetes risk as we had access to
detailed treatment data, including relapse treatment.
Survivors of testicular cancer could be more health-conscious
than their peers in the general population which can have
inﬂuenced their lifestyle following testicular cancer treatment.
Since diabetes in part depends on life-style, this may explain the
unincreased risk of diabetes among irradiated patients compared
to the general population. We did not ﬁnd evidence for a more
healthy lifestyle at diagnosis among irradiated and non-irradiated
patients in the subcohort. Prevalence of smoking did not differ
between these patients and smoking at diagnosis was not
associated with diabetes risk. Although BMI above 30 kg/m2 was
associated with diabetes risk, prevalence of diabetes was similar in
both groups. We found no evidence for confounding nor for
modiﬁcation of the radiation associated diabetes risk by BMI,
although imputation was necessary since for approximately 40%
of the patients either weight or height was missing. A limitation of
our general population comparisons is left-censoring in the
analysis due to lack of reference data before 2002, resulting in
exclusion of many person-years from analysis, mainly affecting
patients treated in the distant past who were more frequently
irradiated.
Although infradiaphragmatic radiotherapy is currently largely
abandoned in treatment of stage I seminoma, while stage II
seminoma patients with increased risk of metastatic disease still
have an indication for radiotherapy, the association of previous
para-aortic irradiation with diabetes risk is still very relevant for
many long-term TC survivors. Radiotherapy techniques have
improved over the past decades, with increasing use of CT
planning since the late ‘90s, which has resulted in more tailored
abdominal RT ﬁelds. However, this did not necessarily decrease
radiation ﬁeld width in our study. In some cases, the amount of
irradiated tissue near the renal hilum may even have increased
over time. Currently, there are still no recommended constraints
for the radiation dose to the pancreatic gland. We expect
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Fig. 2 Risk of diabetes by prescribed para-aortic radiation dose
among testicular cancer survivors. HRs for diabetes risk for
prescribed dose categories are plotted at the mean dose within
each category (26 Gy for ≤26GY, 30 Gy for 27–32 Gy and 40 Gy for
≥33 Gy). Vertical lines represent the 95% CI for each category of
dose. The HRs for determining the excess risk increase per 10 Gray
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therefore that the change in the pancreatic volume included
within the para-aortic radiation ﬁeld over time was limited. In
more recently irradiated patients diabetes risk may be lower due
to the use of more precise intensity modulated radiotherapy
techniques, exposing a lower proportion of the pancreas to a
relatively high radiation dose. Nonetheless, this study suggests
another reason why stage I seminoma patients may beneﬁt from
surveillance above undergoing PAO-RT, beyond the observation
that the 5-year relapse rate of 4–6% for patients without
prognostic risk factors under surveillance protocols27,28 is not that
different from the 4% 5-year relapse rate after abdominal RT.27,29
In conclusion, TC survivors treated with para-aortic irradiation
have a 1.66-fold higher risk of diabetes compared to TC survivors
treated with surgery only. Although diabetes risk is only
moderately increased after para-aortic irradiation, and the relative
risk in our study is lower compared to the risks observed in
childhood cancer survivors, early detection and treatment of
diabetes may prevent or alleviate late vascular damage and CVD.
With the current improvements in radiation techniques the dose
to organs at risk can be reduced, especially if the pancreas is
deﬁned as an organ at risk which is also important in radiation
treatment of other malignancies. Unfortunately the optimal dose
constraint cannot be derived from this study, although our study
suggests to keep the dose to the pancreas below 26 Gray. This
novel ﬁnding does not only apply to irradiated TC patients, but
potentially also to patients with abdominal lymphoma, cervical
cancer or stomach cancer who receive abdominal irradiation.
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